Summary

Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress syndrome, or ARDS. A frequent cause of death during the COVID-19 pandemic, ARDS occurs when an inflammatory cascade triggered by infection or injury leaks fluid into the lungs, crashing blood oxygen levels. Nearly 40% of people affected die. A proof-of-concept study led by a scientist at the University of Florida suggests a monoclonal antibody that targets a master regulator of inflammation, called NAMPT, could offer much-needed treatment for ARDS.

AI summaries can be wrong sometimes—always verify important details using the source article.